ASCIERTO, PAOLO ANTONIO
ASCIERTO, PAOLO ANTONIO
DIPARTIMENTO DI NEUROSCIENZE E SCIENZE RIPRODUTTIVE ED ODONTOSTOMATOLOGICHE
miR-579-3p is a novel master regulator of melanoma progression and drug resistance in metastatic melanoma
2016 Ascierto, P
Melanoma Bridge 2013: Poster and Oral Presentations Abstracts
2014 Ascierto, P
Intermediate dose recombinant interferon-alpha as second-line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon
2000 Ascierto, P; Daponte, A; Parasole, R; Perrone, F; Caraco, C; Melucci, Mt; Palmieri, G; Napolitano, M; Mozzillo, N; Castello, G
Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers
2017 Ascierto, P
Melanoma Bridge 2013: Poster and Oral Presentations Abstracts
2014 Ascierto, P
Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti-PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations
2017 Ascierto, P
Pattern and distribution of BRAF/NRAS and P16(CDKN2A) mutations among primary an secondary lesions in melanoma patients
2012 Ascierto, P
Molecular Pathogenesis of Melanoma: Established and Novel Pathways
2012 Ascierto, P; Ascierto, Ml; Capone, M; Elaba, Z; Murphy, Mj; And Palmieri, G
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study
2014 Larkin, J; Del Vecchio, M; Ascierto, P; Krajsova, I; Schachter, J; Neyns, B; Espinosa, E; Garbe, C; Sileni, Vc; Gogas, H; Miller, Wh; Mandala, M; Hospers, Gap; Arance, A; Queirolo, P; Hauschild, A; Brown, Mp; Mitchell, L; Veronese, L; Blank, Cu
Prognostic value of CD40 in adult soft tissue sarcomas
2004 Ottaiano, A; De Chiara, A; Perrone, F; Botti, G; Fazioli, F; De Rosa, V; Mozzillo, N; Ravo, V; Morrica, B; Gallo, C; Pisano, C; Napolitano, M; Ascierto, P; Laffaioli, Rv; Apice, G
CD40 activation as potential tool in malignant neoplasms
2002 Ottaiano, A; Pisano, C; De Chiara, A; Ascierto, P; Botti, G; Barletta, E; Apice, G; Gridelli, C; Iaffaioli, Vr
Expanded access programmes: patient interests versus clinical trial integrity
2015 Ascierto, P
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
2012 Di Giacomo, Am; Ascierto, P; Pilla, L; Santinami, M; Ferrucci, Pf; Giannarelli, D; Marasco, A; Rivoltini, L; Simeone, E; Nicoletti, Svl; Fonsatti, E; Annesi, D; Queirolo, P; Testori, A; Ridolfi, R; Parmiani, G; Maio, M
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
2020 Gutzmer, R; Stroyakovskiy, D; Gogas, H; Robert, C; Lewis, K; Protsenko, S; Pereira, Rp; Eigentler, T; Rutkowski, P; Demidov, L; Manikhas, Gm; Yan, Yb; Huang, Kc; Uyei, A; Mcnally, V; Mcarthur, Ga; Ascierto, P
Regional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial (CheckMate 067)
2017 Ascierto, P
Association of depth of response with survival outcomes in prognostic groups of patients treated with cobimetinib (C) +/- vemurafenib (V): A pooled analysis of the BRIM-2,-3,-7, and coBRIM studies
2017 Ascierto, P
A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600-mutant melanoma (COMBI-i)
2017 Ascierto, P
Contents and quality of prospective clinical trials of biotherapies in solid tumors: A five-year survey
2005 Ascierto, P
Low-dose temozolomide modulation of peripheral blood regulatory T cells before dendritic cell-based vaccination in metastatic melanoma: Phase I/II study
2010 Ascierto, P
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: Data from the Italian cohort of ipilimumab expanded access programme (EAP)
2013 Ascierto, P